このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Bio-Rad Laboratories バランスシートの健全性
財務の健全性 基準チェック /46
Bio-Rad Laboratoriesの総株主資本は$9.1B 、総負債は$1.2Bで、負債比率は13.1%となります。総資産と総負債はそれぞれ$12.6Bと$3.6Bです。 Bio-Rad Laboratoriesの EBIT は$355.6Mで、利息カバレッジ比率-10.1です。現金および短期投資は$1.6Bです。
主要情報
13.1%
負債資本比率
US$1.19b
負債
| インタレスト・カバレッジ・レシオ | -10.1x |
| 現金 | US$1.65b |
| エクイティ | US$9.05b |
| 負債合計 | US$3.56b |
| 総資産 | US$12.61b |
財務の健全性に関する最新情報
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Recent updates
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet
May 02Bio-Rad Offers Value If You Look
Mar 28Bio-Rad Laboratories: Relentless Growth Supports A Bullish Outlook
Dec 25Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Dec 10財務状況分析
短期負債: BIOの 短期資産 ( $3.1B ) が 短期負債 ( $466.2M ) を超えています。
長期負債: BIOの短期資産 ( $3.1B ) は 長期負債 ( $3.1B ) をカバーしていません。
デット・ツー・エクイティの歴史と分析
負債レベル: BIO総負債よりも多くの現金を保有しています。
負債の削減: BIOの負債対資本比率は、過去 5 年間で8.8%から13.1%に増加しました。
債務返済能力: BIOの負債は 営業キャッシュフロー によって 十分にカバー されています ( 29.1% )。
インタレストカバレッジ: BIO支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。